Central Pharmaceutical Joint Stock Company No3: Q1 2026 saw robust revenue and profit growth, higher margins, and improved cash flow

About this update from Central Pharmaceutical Jsc No. 3

Net revenue and profit after tax for Q1 2026 grew 47% and 46% year-over-year, respectively, with improved gross margin and strong cash flow from operations. Short-term borrowings and tax obligations decreased, while retained earnings rose sharply.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Central Pharmaceutical Jsc No. 3